Amid concerns about a potential link between paclitaxel devices and heightened long-term mortality rates, Medtronic (NYSE:MDT) and other device-makers doubled down on their products’ safety at this year’s Leipzig Interventional Course in Germany.
Medtronic presented a patient-level survival analysis that included 1,837 patients enrolled in its In.Pact Admiral clinical program.
Get the full story at our sister site, Drug Delivery Business News.
The post LINC 2019: Medtronic, Boston Scientific back paclitaxel devices amid safety probe appeared first on MassDevice.